We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Marrone Bio's (MBII) Q1 Loss in Line, Revenues Up Y/Y
Read MoreHide Full Article
Marrone Bio Innovations, Inc. posted a loss of $7.6 million or 31 cents per share in first-quarter 2017, narrower than a loss of $9.3 million or 38 cents per share a year ago. Loss per share for the quarter was in line with the Zacks Consensus Estimate. The bottom line in the reported quarter was supported by healthy revenues and margin growth.
Gross margin for the quarter was 45.1%, a significant improvement from 15% recorded a year ago. The company gained from improved capacity utilization and better product mix in the quarter.
Revenues & Shipments
Marrone Bio’s revenues soared 56% year over year to $4.2 million in the quarter. The company benefited from higher adoption of its products by farmers, expanded product labelling and growth in its customer base and specific overseas markets.
Product shipments jumped 66% year over year to $6.5 million in the quarter. This marked the second straight quarter the company has logged record product shipment levels.
Marrone Bio Innovations, Inc. Price, Consensus and EPS Surprise
Marrone Bio ended the quarter with cash and cash equivalents of around $1.8 million, down around 82% year over year. Long-term debt was $21 million, down around 2% year over year. Net cash used in operations was roughly $7.6 million in the quarter, an improvement from $9.7 million of cash used a year ago.
Outlook
Moving ahead, Marrone Bio said that it is well placed to maintain the healthy momentum and capture technology-driven opportunities to create meaningful value for its customers and shareholders. The company is looking to leverage its customer relationships and its comprehensive and growing portfolio of bio-based solutions to meet a vast range of unmet pest and disease challenges.
Price Performance
Marrone Bio has significantly outperformed the Zacks categorized Chemicals-Diversified industry over a year. The company’s shares have rallied around 131.3% over this period compared with the industry’s gain of 17.5% over the same period.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Marrone Bio's (MBII) Q1 Loss in Line, Revenues Up Y/Y
Marrone Bio Innovations, Inc. posted a loss of $7.6 million or 31 cents per share in first-quarter 2017, narrower than a loss of $9.3 million or 38 cents per share a year ago. Loss per share for the quarter was in line with the Zacks Consensus Estimate. The bottom line in the reported quarter was supported by healthy revenues and margin growth.
Gross margin for the quarter was 45.1%, a significant improvement from 15% recorded a year ago. The company gained from improved capacity utilization and better product mix in the quarter.
Revenues & Shipments
Marrone Bio’s revenues soared 56% year over year to $4.2 million in the quarter. The company benefited from higher adoption of its products by farmers, expanded product labelling and growth in its customer base and specific overseas markets.
Product shipments jumped 66% year over year to $6.5 million in the quarter. This marked the second straight quarter the company has logged record product shipment levels.
Marrone Bio Innovations, Inc. Price, Consensus and EPS Surprise
Marrone Bio Innovations, Inc. Price, Consensus and EPS Surprise | Marrone Bio Innovations, Inc. Quote
Financials
Marrone Bio ended the quarter with cash and cash equivalents of around $1.8 million, down around 82% year over year. Long-term debt was $21 million, down around 2% year over year. Net cash used in operations was roughly $7.6 million in the quarter, an improvement from $9.7 million of cash used a year ago.
Outlook
Moving ahead, Marrone Bio said that it is well placed to maintain the healthy momentum and capture technology-driven opportunities to create meaningful value for its customers and shareholders. The company is looking to leverage its customer relationships and its comprehensive and growing portfolio of bio-based solutions to meet a vast range of unmet pest and disease challenges.
Price Performance
Marrone Bio has significantly outperformed the Zacks categorized Chemicals-Diversified industry over a year. The company’s shares have rallied around 131.3% over this period compared with the industry’s gain of 17.5% over the same period.
Zacks Rank & Key Picks
Marrone Bio is a Zacks Rank #3 (Hold) stock.
Better-placed companies in the chemical space include Huntsman Corporation (HUN - Free Report) , Kronos Worldwide, Inc. (KRO - Free Report) and The Chemours Company (CC - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Huntsman has expected long-term growth of 7%.
Kronos has expected long-term growth of 5%.
Chemours has expected long-term growth of 15.5%.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>